Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey L Uy

Showing results (31-40 of 146) with videos related to

Pageof 15
Sort By:
Blood Advances|April 20, 2022
Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AMLGeoffrey L Uy, Laura F Newell, Tara L Lin, et al.
Haematologica|December 2, 2021
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemiaSumithira Vasu, Jessica K Altman, Geoffrey L Uy, et al.
Leukemia Research|October 16, 2015
Targeting bone marrow lymphoid niches in acute lymphoblastic leukemiaGeoffrey L Uy, Yen-Michael S Hsu, Amy P Schmidt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 22, 2017
Fresh or Cryopreserved CD34<sup>+</sup>-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell TransplantationArmin Ghobadi, Mark A Fiala, Giridharan Ramsingh, et al.
Blood Reviews|March 16, 2024
Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?Geoffrey L Uy, Daniel J DeAngelo, Jay N Lozier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2017
T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid LeukemiaJoan How, Michael Slade, Khoan Vu, et al.
Transplantation and Cellular Therapy|November 11, 2025
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate E-Selectin Inhibition with Uproleselan to Reduce Gastrointestinal Toxicity During Autologous Hematopoietic Cell Transplantation for Multiple MyelomaZachary D Crees, Keith Stockerl-Goldstein, Meaghan Ryan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 31, 2016
Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell TransplantIbraheem H Motabi, Armin Ghobadi, Jingxia Liu, et al.
Blood Advances|October 17, 2024
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapyGeoffrey L Uy, Vinod Pullarkat, Praneeth Baratam, et al.
Blood|November 6, 2010
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemiaTodd A Fehniger, Geoffrey L Uy, Kathryn Trinkaus, et al.
Pageof 15

Showing results (31-40 of 146) with videos related to

Sort By:
Pageof 15
Blood Advances|April 20, 2022
Transplant outcomes after CPX-351 vs 7 + 3 in older adults with newly diagnosed high-risk and/or secondary AMLGeoffrey L Uy, Laura F Newell, Tara L Lin, et al.
Haematologica|December 2, 2021
A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemiaSumithira Vasu, Jessica K Altman, Geoffrey L Uy, et al.
Leukemia Research|October 16, 2015
Targeting bone marrow lymphoid niches in acute lymphoblastic leukemiaGeoffrey L Uy, Yen-Michael S Hsu, Amy P Schmidt, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 22, 2017
Fresh or Cryopreserved CD34<sup>+</sup>-Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell TransplantationArmin Ghobadi, Mark A Fiala, Giridharan Ramsingh, et al.
Blood Reviews|March 16, 2024
Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?Geoffrey L Uy, Daniel J DeAngelo, Jay N Lozier, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2017
T Cell-Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid LeukemiaJoan How, Michael Slade, Khoan Vu, et al.
Transplantation and Cellular Therapy|November 11, 2025
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate E-Selectin Inhibition with Uproleselan to Reduce Gastrointestinal Toxicity During Autologous Hematopoietic Cell Transplantation for Multiple MyelomaZachary D Crees, Keith Stockerl-Goldstein, Meaghan Ryan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 31, 2016
Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell TransplantIbraheem H Motabi, Armin Ghobadi, Jingxia Liu, et al.
Blood Advances|October 17, 2024
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapyGeoffrey L Uy, Vinod Pullarkat, Praneeth Baratam, et al.
Blood|November 6, 2010
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemiaTodd A Fehniger, Geoffrey L Uy, Kathryn Trinkaus, et al.
Pageof 15